FY2029 Earnings Forecast for KYMR Issued By HC Wainwright

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – HC Wainwright boosted their FY2029 earnings estimates for shares of Kymera Therapeutics in a research report issued on Tuesday, December 9th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($2.61) for the year, up from their previous forecast of ($2.99). HC Wainwright currently has a “Buy” rating and a $134.00 price target on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share.

KYMR has been the topic of several other reports. Piper Sandler reissued an “overweight” rating and issued a $125.00 target price (up from $98.00) on shares of Kymera Therapeutics in a report on Tuesday. Jefferies Financial Group raised their price objective on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a research note on Tuesday. Bank of America upped their target price on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, B. Riley upped their price target on Kymera Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Friday, October 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $112.80.

Kymera Therapeutics Stock Up 2.1%

Kymera Therapeutics stock opened at $89.68 on Thursday. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $103.00. The company has a market capitalization of $6.45 billion, a P/E ratio of -24.98 and a beta of 2.28. The stock’s 50 day moving average is $64.77 and its 200 day moving average is $51.85.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The business had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.17, for a total transaction of $8,917,000.00. Following the completion of the transaction, the chief executive officer owned 660,482 shares in the company, valued at $58,895,179.94. This trade represents a 13.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Jared Gollob sold 59,576 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the transaction, the insider owned 109,992 shares of the company’s stock, valued at $6,755,708.64. This trade represents a 35.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 597,805 shares of company stock valued at $46,839,199 in the last 90 days. 16.01% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Farther Finance Advisors LLC increased its stake in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares during the period. PNC Financial Services Group Inc. grew its stake in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after acquiring an additional 770 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares during the period. Osaic Holdings Inc. increased its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares during the period. Finally, Bessemer Group Inc. raised its position in Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.